Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_4
2
33%
Ph not_applicable
1
17%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 33 (50.0%)
Phase 42 (33.3%)
N/A1 (16.7%)

Trials by Status

unknown117%
terminated117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

NCT00930943
terminatedphase_3

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
completedphase_4

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

NCT00955110
completedphase_3

Open Label Assessment of Long-Term Safety and Utility

NCT00904449
unknownnot_applicable

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

NCT00945919
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00930943Phase 4

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Completed
NCT00765856Phase 3

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

Terminated
NCT00955110Phase 4

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Completed
NCT00904449Phase 3

Open Label Assessment of Long-Term Safety and Utility

Completed
NCT00945919Not Applicable

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Unknown
NCT00904280Phase 3

Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6